Are there certain clinical features that help you choose between benralizumab and mepolizumab for EGPA in clinical practice?   

Not specifically. Both of these medications are effective in controlling severe asthma and allow for OCS reduction in EGPA patients, though benra did demonstrate more serum eosinophil depletion. The MANDARA trial demonstrated non-inferiority so both of these medications and MOAs are effective. Patie...

Given, as noted above, no significant clinical differences between benralizumab and mepolizumab, assuming there are no specific insurance differences between the two, I preferentially prescribe benralizumab because of the 8-week dosing frequency after the first three 4-week loading doses. For a few ...